長田 太助 ながた だいすけ 先生

来歴等

略歴

1992年　東京大学医学部医学科
2000年　東京大学大学院医学研究科内科学修了（医学博士）
2000年　米国ボストン大学　博士研究員
2004年　国立病院機構京都医療センター　室長
2006年　東京大学医学部循環器内科　助教
2008年　東京大学大学院　特任准教授
2011年　獨協医科大学循環器・腎臓内科　准教授
2013年　自治医科大学内科学講座腎臓内科学部門　教授

論文

【論文】
1. Kohara M, Masuda T, Shiizaki K, Akimoto T, Watanabe Y, Honma S, Sekiguchi C, Miyazawa Y, Kusano E, Kanda Y, Asano Y, Kuro OM, Nagata D: Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease. PLoS One. 2017;12:e0178971
2. Morishita Y, Yoshizawa H, Watanabe M, Imai R, Imai T, Hirahara I, Akimoto T, Ookawara S, Muto S, Nagata D: Microrna expression profiling in peritoneal fibrosis. Transl Res. 2016;169:47-66
3. Morishita Y, Ookawara S, Hirahara I, Muto S, Nagata D: Hif-1alpha mediates hypoxia-induced epithelial-mesenchymal transition in peritoneal mesothelial cells. Ren Fail. 2016;38:282-289
4. Masuda T, Murakami T, Igarashi Y, Okabe K, Kobayashi T, Takeda SI, Saito T, Sekiguchi C, Miyazawa Y, Akimoto T, Saito O, Muto S, Nagata D: Dual impact of tolvaptan on intracellular and extracellular water in chronic kidney disease patients with fluid retention. Intern Med. 2016;55:2759-2764
5. Hirahara I, Kusano E, Morishita Y, Inoue M, Akimoto T, Saito O, Muto S, Nagata D: Matrix metalloproteinase-2 as a superior biomarker for peritoneal deterioration in peritoneal dialysis. World J Nephrol. 2016;5:204-212
6. Yoshizawa H, Morishita Y, Watanabe M, Ishibashi K, Muto S, Kusano E, Nagata D: Tgf-beta(1)-sirna delivery with nanoparticles inhibits peritoneal fibrosis. Gene Ther. 2015;22:333-340
7. Satonaka H, Nagata D, Takahashi M, Kiyosue A, Myojo M, Fujita D, Ishimitsu T, Nagano T, Nagai R, Hirata Y: Involvement of p2y12 receptor in vascular smooth muscle inflammatory changes via mcp-1 upregulation and monocyte adhesion. Am J Physiol Heart Circ Physiol. 2015;308:H853-861
8. Otani-Takei N, Masuda T, Akimoto T, Honma S, Watanabe Y, Shiizaki K, Miki T, Kusano E, Asano Y, Kuro OM, Nagata D: Association between serum soluble klotho levels and mortality in chronic hemodialysis patients. Int J Endocrinol. 2015;2015:406269
9. Onishi A, Akimoto T, Urabe M, Hirahara I, Muto S, Ozawa K, Nagata D, Kusano E: Attenuation of methylglyoxal-induced peritoneal fibrosis: Immunomodulation by interleukin-10. Lab Invest. 2015;95:1353-1362
10. Morishita Y, Nagata D: Strategies to improve physical activity by exercise training in patients with chronic kidney disease. Int J Nephrol Renovasc Dis. 2015;8:19-24
11. Morishita Y, Imai T, Yoshizawa H, Watanabe M, Ishibashi K, Muto S, Nagata D: Delivery of microrna-146a with polyethylenimine nanoparticles inhibits renal fibrosis in vivo. Int J Nanomedicine. 2015;10:3475-3488
12. Komada T, Usui F, Kawashima A, Kimura H, Karasawa T, Inoue Y, Kobayashi M, Mizushina Y, Kasahara T, Taniguchi S, Muto S, Nagata D, Takahashi M: Role of nlrp3 inflammasomes for rhabdomyolysis-induced acute kidney injury. Sci Rep. 2015;5:10901
13. Kimura T, Akimoto T, Watanabe Y, Kurosawa A, Nanmoku K, Muto S, Kusano E, Yagisawa T, Nagata D: Impact of renal transplantation and nephrectomy on urinary soluble klotho protein. Transplant Proc. 2015;47:1697-1699
14. Iwazu Y, Komori S, Nagata D: Change of chylous ascites during low-density lipoprotein apheresis in a patient with idiopathic nephrotic syndrome. Ther Apher Dial. 2015;19:97-98
15. Ito C, Akimoto T, Miki T, Kusano E, Nagata D: Prevalence of colorectal carcinoma in ckd patients in pre-dialysis and during the dialysis introduction period. Clin Exp Nephrol. 2015;19:148-149
16. Imai T, Akimoto T, Ito C, Masuda T, Nagata D: Management of diabetes associated with nephrotic syndrome: Therapeutic potential of dapagliflozin for protracted volume retention. Drug Target Insights. 2015;9:29-31
17. Hirahara I, Sato H, Imai T, Onishi A, Morishita Y, Muto S, Kusano E, Nagata D: Methylglyoxal induced basophilic spindle cells with podoplanin at the surface of peritoneum in rat peritoneal dialysis model. Biomed Res Int. 2015;2015:289751
18. Onishi A, Akimoto T, Morishita Y, Hirahara I, Inoue M, Kusano E, Nagata D: Peritoneal fibrosis induced by intraperitoneal methylglyoxal injection: The role of concurrent renal dysfunction. Am J Nephrol. 2014;40:381-390
19. Myojo M, Nagata D, Fujita D, Kiyosue A, Takahashi M, Satonaka H, Morishita Y, Akimoto T, Nagai R, Komuro I, Hirata Y: Telmisartan activates endothelial nitric oxide synthase via ser1177 phosphorylation in vascular endothelial cells. PLoS One. 2014;9:e96948
20. Morishita Y, Yoshizawa H, Watanabe M, Ishibashi K, Muto S, Kusano E, Nagata D: Sirnas targeted to smad4 prevent renal fibrosis in vivo. Sci Rep. 2014;4:6424
21. Morishita Y, Kusano E, Nagata D: Clinical implication of the renin-angiotensin-aldosterone blockers in chronic kidney disease undergoing hemodialysis. Open Cardiovasc Med J. 2014;8:6-11
22. Tanaka K, Nagata D, Hirata Y, Tabata Y, Nagai R, Sata M: Augmented angiogenesis in adventitia promotes growth of atherosclerotic plaque in apolipoprotein e-deficient mice. Atherosclerosis. 2011;215:366-373
23. Kiyosue A, Nagata D, Myojo M, Sato T, Takahashi M, Satonaka H, Nagai R, Hirata Y: Aldosterone-induced osteopontin gene transcription in vascular smooth muscle cells involves glucocorticoid response element. Hypertens Res. 2011;34:1283-1287
24. Nagata D, Hirata Y: The role of amp-activated protein kinase in the cardiovascular system. Hypertens Res. 2010;33:22-28
25. Kiyosue A, Hirata Y, Ando J, Fujita H, Morita T, Takahashi M, Nagata D, Kohro T, Imai Y, Nagai R: Relationship between renal dysfunction and severity of coronary artery disease in japanese patients. Circ J. 2010;74:786-791
26. Kiyosue A, Hirata Y, Ando J, Fujita H, Morita T, Takahashi M, Nagata D, Kohro T, Imai Y, Nagai R: Plasma cystatin c concentration reflects the severity of coronary artery disease in patients without chronic kidney disease. Circ J. 2010;74:2441-2447
27. Hirata Y, Nagata D, Suzuki E, Nishimatsu H, Suzuki J, Nagai R: Diagnosis and treatment of endothelial dysfunction in cardiovascular disease. Int Heart J. 2010;51:1-6
28. Takaoka M, Nagata D, Kihara S, Shimomura I, Kimura Y, Tabata Y, Saito Y, Nagai R, Sata M: Periadventitial adipose tissue plays a critical role in vascular remodeling. Circ Res. 2009;105:906-911
29. Nagata D, Kiyosue A, Takahashi M, Satonaka H, Tanaka K, Sata M, Nagano T, Nagai R, Hirata Y: A new constitutively active mutant of amp-activated protein kinase inhibits anoxia-induced apoptosis of vascular endothelial cell. Hypertens Res. 2009;32:133-139
30. Nagata D, Takahashi M, Sawai K, Tagami T, Usui T, Shimatsu A, Hirata Y, Naruse M: Molecular mechanism of the inhibitory effect of aldosterone on endothelial no synthase activity. Hypertension. 2006;48:165-171
31. Zang M, Zuccollo A, Hou X, Nagata D, Walsh K, Herscovitz H, Brecher P, Ruderman NB, Cohen RA: Amp-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human hepg2 cells. J Biol Chem. 2004;279:47898-47905
32. Nagata D, Takeda R, Sata M, Satonaka H, Suzuki E, Nagano T, Hirata Y: Amp-activated protein kinase inhibits angiotensin ii-stimulated vascular smooth muscle cell proliferation. Circulation. 2004;110:444-451
33. Nagata D, Mogi M, Walsh K: Amp-activated protein kinase (ampk) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress. J Biol Chem. 2003;278:31000-31006
34. Zou MH, Hou XY, Shi CM, Nagata D, Walsh K, Cohen RA: Modulation by peroxynitrite of akt- and amp-activated kinase-dependent ser1179 phosphorylation of endothelial nitric oxide synthase. J Biol Chem. 2002;277:32552-32557
35. Nagata D, Suzuki E, Nishimatsu H, Satonaka H, Goto A, Omata M, Hirata Y: Transcriptional activation of the cyclin d1 gene is mediated by multiple cis-elements, including sp1 sites and a camp-responsive element in vascular endothelial cells. J Biol Chem. 2001;276:662-669
36. Suzuki E, Nagata D, Yoshizumi M, Kakoki M, Goto A, Omata M, Hirata Y: Reentry into the cell cycle of contact-inhibited vascular endothelial cells by a phosphatase inhibitor. Possible involvement of extracellular signal-regulated kinase and phosphatidylinositol 3-kinase. J Biol Chem. 2000;275:3637-3644
37. Nagata D, Suzuki E, Nishimatsu H, Yoshizumi M, Mano T, Walsh K, Sata M, Kakoki M, Goto A, Omata M, Hirata Y: Cyclin a downregulation and p21(cip1) upregulation correlate with gata-6-induced growth arrest in glomerular mesangial cells. Circ Res. 2000;87:699-704
38. Nagata D, Hirata Y, Suzuki E, Kakoki M, Hayakawa H, Goto A, Ishimitsu T, Minamino N, Ono Y, Kangawa K, Matsuo H, Omata M: Hypoxia-induced adrenomedullin production in the kidney. Kidney Int. 1999;55:1259-1267

著書

【著書】
内科学第11版（分担執筆）、朝倉書店、2017年
今日の治療指針2017（分担執筆）、医学書院、2017年

その他

• 【受賞】 日本心臓財団動脈硬化Update研究奨励賞、2004年

• 【受賞】日本心血管内分泌代謝学会若手研究奨励賞、2004年

• 【受賞】日本心脈管作動物質学会研究奨励賞、2006年

• 【受賞】関湊賞、2012年